Dr Reddy's to focus on peptides, biosimilars to drive FY27 growth
This story was originally published at 18:59 IST on 2 July 2026
Register to read our real-time news.Informist, Thursday, Jul. 2, 2026
NEW DELHI – Dr. Reddy's Laboratories Ltd. plans to strengthen its base business driven by the growth in peptides, biosimilars, consumer healthcare, and innovation-led therapies in 2026-27 (Apr-Mar). "As we enter FY2027 (FY27), our priorities are clear. We will continue to strengthen our base business while building future growth drivers across peptides, biosimilars, consumer healthcare, and innovation-led therapies," the company said in its annual report for FY26.
The company's strategy will continue to centre on strengthening its generics and active pharmaceutical ingredients businesses through differentiated product launches, targeted research and development, and supply-chain reliability, while expanding consumer healthcare portfolio and innovation-led businesses through partnerships and licensing agreements, it said.
For FY26, Dr. Reddy's reported a consolidated net profit of INR 41.96 billion, down almost 26% on year. Its revenue during the year rose over 3% on year to INR 337.00 billion. Dr. Reddy's expects biosimilars to emerge as a key growth driver, while remaining committed to building a differentiated global oncology business through a combination of internal innovation and partnership.
"Our goal is to enhance global accessibility to biosimilar treatments through a combination of in-house development and strategic partnerships. After successfully introducing numerous biosimilar products in India and other developing markets, we are gradually expanding operations into stringently regulated territories," the company said.
Dr. Reddy's expects glucagon-like peptide-1 therapies to be a key growth driver, building on the launch of generic semaglutide in India and its approval in Canada during FY26. The company said its entry into the glucagon-like peptide-1 segment reflects its capabilities in complex product development and peptide science, and positions it to expand its presence in the diabetes and obesity treatment market. It added that generic semaglutide has broadened affordable access to metabolic therapies.
"We also aim to introduce generic semaglutide in several countries and, through our ‘One Product, One Quality' approach, ensure consistent high-quality standards across all markets," the annual report said.
For the March quarter, the company reported consolidated net profit of INR 2.21 billion on revenues of INR 75.46 billion. The net profit included an impairment loss of INR 2.28 billion related to Chimeric Antigen Receptor T-cell therapy and the discontinuation of the phase 3 study of non-small cell lung cancer conducted by Immutep Ltd.
On Thursday, the company's shares ended at INR 1,345.70 on the National Stock Exchange, up 0.4% from the previous close. End
Reported by Gunjan Rajput
Edited by Saji George Titus
For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.
Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.
Informist Media Tel +91 (11) 4220-1000
Send comments to feedback@informistmedia.com
© Informist Media Pvt. Ltd. 2026. All rights reserved.
To read more please subscribe
Share this Story:
